港股異動丨威高股份(1066.HK)跌4.5% 遭投行降評級和目標價
格隆匯9月9日丨威高股份(1066.HK)跌4.5%,報16.98港元,總市值768億港元。威高股份上半年收入及純利分別按年增長3%及3.5%。野村近日發表研究報告指出,業績增長主要是受到骨科產品、預充式注射器及血液管理業務的強勁增長所帶動。期內,臨牀護理及傷害處理銷售分別按年下跌10.4%及17.9%,主要是因為手術量及住院服務下降所致。基於骨科產品的銷售增長高於預期,該行將公司2020及2021財年的收入預測分別上調1.7%及0.9%。隨着國家藥品集中採購在全國進一步整合,對於公司的平均售價增長預測更為保守,目標價由原來的21.9港元下調至20.3港元,投資評級由“買入”下調至“中性”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.